3 news items
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
BMY
TSVT
5 Apr 24
genuine and authentic to our "why" and keeping our people and culture top of mind every day.
For more
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
BMY
2 Apr 24
builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
BMY
TSVT
15 Mar 24
to our "why" and keeping our people and culture top of mind every day.
For more information, visit
- Prev
- 1
- Next